FIGURE 1.
The process of TTFields clinical trials on typical tumor types.
FIGURE 2.
Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)
EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide
FIGURE 3.
Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).
EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928
FIGURE 4.
Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).
AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival
FIGURE 5.
Researches on potential mechanisms of TTFields action.